Neuren Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Neuren Pharmaceuticals has a total shareholder equity of A$219.2M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$228.2M and A$9.0M respectively. Neuren Pharmaceuticals's EBIT is A$155.2M making its interest coverage ratio -14.3. It has cash and short-term investments of A$213.2M.
Key information
0%
Debt to equity ratio
AU$0
Debt
| Interest coverage ratio | -14.3x |
| Cash | AU$213.17m |
| Equity | AU$219.15m |
| Total liabilities | AU$9.00m |
| Total assets | AU$228.15m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NK9's short term assets (A$228.0M) exceed its short term liabilities (A$9.0M).
Long Term Liabilities: NK9's short term assets (A$228.0M) exceed its long term liabilities (A$29.0K).
Debt to Equity History and Analysis
Debt Level: NK9 is debt free.
Reducing Debt: NK9 has not had any debt for past 5 years.
Debt Coverage: NK9 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NK9 has no debt, therefore coverage of interest payments is not a concern.